Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
Blueprint Medicines Corp (BPMC)
Sector: Healthcare; Industry: Biotechnology

Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-03-03 Hurley Ariel Principal Accounting Officer Sell 512 $98.45 $50,406 No
2021-03-15 Haviland Kate Chief Operating Officer Sell 1,000 $105.60 $105,603 Yes
2021-03-04 Durso-Bumpus Debra Chief People Officer Sell 1,693 $86.76 $146,887 No
2021-03-04 Hurley Ariel Principal Accounting Officer Sell 1,372 $91.16 $125,066 No
2021-03-04 Haviland Kate Chief Operating Officer Sell 1,952 $86.77 $169,370 No
2021-03-04 Landsittel Michael Chief Financial Officer Sell 1,507 $86.76 $130,749 No
2021-03-04 McCain Tracey L EVP and Chief Legal Officer Sell 1,893 $86.76 $164,242 No
2021-03-04 Murray Christopher K. SVP, Technical Operations Sell 1,210 $86.76 $104,984 No
2021-03-04 Rossi Christina Chief Commercial Officer Sell 1,359 $86.77 $117,920 No
2021-03-04 Albers Jeffrey W. CEO and President Sell 18,986 $89.28 $1,695,006 Yes
2021-03-01 Hurley Ariel Principal Accounting Officer Sell 1,700 $99.51 $169,167 Yes
2021-02-22 Dorsch Marion Chief Scientific Officer Sell 7,578 $100.00 $757,800 Yes
2021-01-04 Demetri George Director Sell 758 $112.15 $85,010 No
2020-12-24 Goldberg Mark Alan Director Sell 5,455 $125.00 $681,875 Yes
2020-12-18 Goldberg Mark Alan Director Sell 5,454 $120.00 $654,480 Yes
2020-12-17 Rowland Charles A Jr Director Sell 10,909 $117.82 $1,285,298 Yes
2020-12-14 Albers Jeffrey W. CEO and President Sell 5,000 $119.18 $595,900 Yes
2020-12-14 Boral Anthony L. Chief Medical Officer Sell 10,000 $118.52 $1,185,200 Yes
2020-12-14 Dorsch Marion Chief Scientific Officer Sell 4,600 $119.00 $547,400 Yes
2020-12-11 Goldberg Mark Alan Director Sell 5,455 $115.00 $627,325 Yes
2020-12-01 Goldberg Mark Alan Director Sell 5,454 $110.00 $599,940 Yes
2020-12-01 Hurley Ariel Principal Accounting Officer Sell 1,038 $109.88 $114,053 Yes
2020-11-16 Haviland Kate Chief Operating Officer Sell 409 $100.27 $41,010 Yes
2020-11-16 Albers Jeffrey W. CEO and President Sell 20,000 $98.71 $1,974,295 Yes
2020-11-16 Hurley Ariel Principal Accounting Officer Sell 1,700 $100.92 $171,564 Yes
2020-11-03 Rossi Christina Chief Commercial Officer Sell 345 $99.69 $34,393 No
2020-11-03 Rowland Charles A Jr Director Sell 10,000 $98.90 $989,011 Yes
2020-10-19 Goldberg Mark Alan Director Sell 5,455 $105.00 $572,775 Yes
2020-10-16 Haviland Kate Chief Operating Officer Sell 13,334 $101.23 $1,349,848 Yes
2020-10-07 Hurley Ariel Principal Accounting Officer Sell 600 $100.00 $60,000 Yes

Insider Smart

SIMON PROPERTY GROUP (SPG) - Bottom fishing the crash could be intimidating, but it can be easier if you know insiders are on your side. Aeppel Glyn, Director of SPG played safe and bought shares in May at $50, but it is not late at all, the stock is now $90.

Insider Smart

SYSCO CORP (SYY) - PELTZ NELSON and Frank Joshua D are insiders of SYSCO CORP, check their transactions to see how they sell high and buy low. Would that be more persuasive than just buy or sell?